Introduction
============

Malaria is still a global concern with around 214 million annual cases and 430,000 annual deaths, mainly among of children younger than 5 ([@B120]). This fatal disease is caused by *Plasmodium* sp. particularly *Plasmodium falciparum* that proliferate in female *Anopheles* mosquitoes ([@B26]). Since the 1940s there has been continuous attempts to halt the spread of the disease and this has succeeded in Europe, North America, and parts of Asia and Latin America ([@B20]). However, not in Sub-Saharan Africa where 80% of the annual malaria patients are found. Besides measures such as vector control and insecticide-treated nets, research and development has led to new drugs and a vaccine. The current preferred therapy is artemisinin combination therapy (ACT) ([@B8]; [@B53]) that is based on artemisinin produced in the natural source *Artemisia annua*. Artemisinin can also be produced heterologously in the plants *Nicotiana benthamiana* and *Physcomitrella patens* ([@B43]; [@B112]; [@B47]). The vaccine toward *Plasmodium* is called PfSPZ and can be produced in *N. benthamiana* and *P. patens* plants ([@B88], [@B87]; [@B14]; [@B34]).

Malaria drugs have contributed significantly to the reductions in malaria mortality and morbidity. The focus for many years has been to screen traditional medicine to find new antimalarial drugs ([@B97]; [@B1]; [@B73]). The malaria drug artemisinin is an example of this and originates from *A. annua*, a Chinese medicinal plant (Qinghao), commonly known as sweet wormwood. It was discovered by the Chinese researcher You-You Tu and her team in 1972, and was named Qinghaosu ([@B52]; [@B108]). Chemically, artemisinin is a sesquiterpene lactone with a unique endoperoxide structure, without the nitrogen containing heterocyclic ring like other antimalarial compounds ([@B62]). The *in planta* accumulation of artemisinin is 0.01--1.4% dry weight depending on the plant variety and artemisinin is stored in the glandular trichomes of *A. annua* ([@B33]; [@B109]; [@B13]; [@B70]). The current production using plants with a "low" content of artemisinin can only just cover the global need, which have led to an increase in price ([@B81]). In 2006, World Health Organization (WHO) recommended artemisinin as the first-choice treatment for malaria. Rapid emergence of antimalarial drug resistance drew attention to formulation of artemisinin-based combination therapy (ACT) with artemisinin as the primary substance and is now the preferred treatment ([@B119]).

To secure the global need of artemisinin, there are continuous and extensive efforts to enhance the production of artemisinin in the native plant *A. annua*. *A. annua* is currently the primary commercial source of artemisinin and significant breeding programs has contributed to higher artemisinin content in the plant ([@B67]; [@B84]; [@B123]), including establishment of mutant libraries ([@B78]). Several plant-breeding techniques have been applied to create superior cultivars of *A. annua*. For example, conventional breeding by crossing *A. annua* with high artemisinin content in wild population has led to hybrid lines with 2% artemisinin d.w ([@B30]; [@B25]). A detailed genetic map of *A. annua* comprising of genes and markers controlling artemisinin yield has been established to generate robust high yielding crops ([@B41]). Identification of *A. annua* superior parental lines with desired traits from these genetic maps has provided two high-yielding hybrids and diallel crossing of the parental lines and the hybrids has showed consistent results for the development of improved *A. annua* hybrids ([@B107]). Doubling the number of chromosomes generated a new variety of tetraploid cultivar with higher artemisinin content and this might become a new elite line ([@B10]). The overall production of the new cultivars from various laboratories have increased the level of artemisinin to about 1 to 2% d.w. ([@B29]; [@B37]; [@B41]; [@B16]), but not all the established plant lines are stable over generations ([@B30]).

Efforts in plant breeding have been challenging due to the heterozygous nature of *A. annua*, which results in transgenic plants with varying degrees of artemisinin content even though they were generated in the same laboratory ([@B30]; [@B41]; [@B54]). This variation is due to the segregation of the heterozygous wild type progeny leading to a different genetic background than the parent plant. Although several high content lines have been created, the unstable yield in the progeny of these cultivars were insufficient to increase the global supply of artemisinin ([@B95]; [@B76]).

Accumulation of artemisinin in *A. annua* is limited to the small 10 cell glandular trichomes (GT) mostly on leaves and other aerial parts ([@B36]; [@B59]; [@B56]). Low GT numbers are correlated to low artemisinin content ([@B41]; [@B51]). Attempts to increase the number of GTs by physical and chemical stress have not been successful ([@B51]). One study expressed the β glucosidase (*bgl*1) gene in *A. annua* through *Agrobacterium*-mediated transformation, which resulted in an increase of GT density by 20% on leaves and 66% on flowers and an increase in artemisinin content of 1.4% in leaves and 2.56% in flowers (d.w). Manipulating GT density together with biosynthetic pathway engineering may further increase artemisinin content in *A. annua*. In depth understanding of *A. annua* GT generation at the molecular level, will broaden the opportunities of increasing the artemisinin production. This approximately though require a greater acceptance of GMO crops in open fields to ensure the global supply.

Plant tissue culture has also been investigated to establish a production of artemisinin in *A. annua* hairy root or cell suspension cultures ([@B72]; [@B7]). Several manipulations of the growth conditions such as different sugar supply, light irradiation, UV-B radiation and chilling treatment have led to production of artemisinin in *A. annua* tissue cultures ([@B118]; [@B57]; [@B114]; [@B7]; [@B124]; [@B79]). Generating somaclonal variants tolerant against salt stress through gamma-rays irradiation has resulted in 13 somaclonal variants (ASV1 to ASV13) of which one of the variants, ASV12 is a stable salt-tolerant line with a higher expression profile of artemisinin key genes (ADS, CYP71AV1, DBR2, and ALDH1) and a higher artemisinin content as compared to wild type. In addition, treatments with elicitors such as methyl jasmonate has significantly increased artemisinin production by up to 49% including up-regulating the expression of artemisinin biosynthesis genes as well as increased GT index (0.128) ([@B7]; [@B113]; [@B28]; [@B122]). Other elicitors such as chitosan, gibberellic acid, and salicylic acid also aid in the accumulation of artemisinin ([@B42]; [@B11]). Combinations of various cultivation and elicitation methods are currently being geared for a mass production of artemisinin in *A. annua* hairy roots via bioreactors with 6.3 g/L dry weight (37.50 g fresh weight) biomass and 0.32 mg/g artemisinin content after 25 days ([@B80]).

Other efforts to enhance artemisinin production have been attempted through genetic engineering of the artemisinin biosynthetic pathway genes in microbial heterologous hosts. Extensive work on the development of microbial production of artemisinin precursors led to semi-synthesis of artemisinin, but this is only partly commercially successful ([@B12]; [@B81]; [@B99]). In this review, the progress and recent bioengineering advances in artemisinin production in stable heterologous *in planta* systems including genetic modifications of *A. annua* is summarized.

Artemisinin Biosynthesis in *Artemisia annua*
=============================================

The biosynthesis of Artemisinin (**Figure [1](#F1){ref-type="fig"}**) has been explored for many years. However, not every detail about the regulation and biosynthesis is completely understood, but the discovery that the whole biosynthesis is located in the glandular trichomes of *A. annua* has facilitated in-depth regulatory studies ([@B75]; [@B74]). Derived from the general terpenoid biosynthesis, two molecules of isopentenyl diphosphate (IPP) and one dimethylallyl diphosphate (DMAPP) are condensed by farnesyl diphosphate synthase (FPPS/FPS) into farnesyl diphosphate (FPP, farnesyl pyrophosphate), the C15 sesquiterpenoid precursor ([@B116]; [@B17]; [@B117]). Overexpression of FPS in *A. annua* resulted in an increase of artemisinin production ([@B44]; [@B9]), which confirms the role of FPS and availability of the substrates in the regulation of artemisinin biosynthesis similar to other sesquiterpene lactones ([@B98]).

![Artemisinin biosynthesis pathway occurs in the glandular trichomes of *Artemisia annua*. The pathway intermediates are defined as FPP, farnesyl diphosphate; AD, amorpha-4,11-diene; AAOH, artemisinic alcohol; AAA, artemisinic aldehyde; AA, artemisinic acid; DHAAA, dihydroartemisinic aldehyde; DHAA, dihydroartemisinic acid. The full name of the enzymes is stated in the text.](fpls-08-01966-g001){#F1}

FPP is converted to amorpha-4,11-diene by amorpha-4,11-diene synthase (ADS) via carbocation formation and cyclization ([@B15]; [@B69]; [@B83], [@B82]). In the following two oxidization steps, amorpha-4,11-diene is hydroxylated into artemisinic alcohol and oxidized to artemisinic aldehyde by amorphadiene monooxygenase (CYP71AV1), a cytochrome P450 enzyme ([@B105]; [@B115]). The activity of the CYP71AV1 has also been confirmed through a knock-out of the endogenous gene in *A. annua* showing that these plants do not produce any downstream products of amorphadiene ([@B27]). It has later been discovered that the alcohol dehydrogenase (ADH1, a dehydrogenase/reductase enzyme) is specific toward artemisinin alcohol and oxidizes this to the aldehyde. This specificity and strong expression in *A. annua* glandular trichomes confirms that ADH1 is responsible for oxidation of artemisinic alcohol to artemisinic aldehyde ([@B74]; [@B76]; [@B45]). Artemisinic aldehyde is further reduced to dihydroartemisinic aldehyde by artemisinic aldehyde Δ11 (13) reductase (DBR2) and subsequently oxidized to dihydroartemisinic acid by aldehyde dehydrogenase (ALDH1), which is also expressed in the trichomes ([@B130]; [@B104]; [@B89]; [@B58]). Besides catalyzing the oxidation of dihydroartemisinic aldehyde to the acid, ALDH1 also catalyzes the oxidation of artemisinic aldehyde to artemisinic acid (a reaction that in yeast is catalyzed by CYP71AV1) ([@B105], [@B104]). Another enzyme, dihydroartemisinic aldehyde reductase (RED1) converts dihydroartemisinic aldehyde to dihydroartemisinic alcohol, a "dead end" substance, which affects the production yield of artemisinin ([@B89]). The final step is a light-induced non-enzymatic spontaneous reaction converting dihydroartemisinic acid to artemisinin and artemisinic acid to arteannuin B ([@B100]; [@B105]; [@B27]).

Bioengineering of Artemisinin Production in Green Plant Cells
=============================================================

Bioengineering of Biosynthetic Genes in *Artemisia annua*
---------------------------------------------------------

Characterization of enzymes in the artemisinin biosynthetic pathway provides new tools and advances the possibility of engineering the production of artemisinin. This can be achieved by enhancing the general terpenoid metabolism and through overexpression of several genes involved in artemisinin biosynthesis in *A. annua* ([@B103]). Overexpression of key terpenoid genes encoding for the enzymes IDI, FPS, HMGR, the plastid targeted DXR and HDR have increased production significantly (some by 2 to 3 fold) in many different studies in *A. annua* ([@B44]; [@B6]; [@B9]; [@B71]; [@B121]; [@B65]). Co-expression of FPS, CYP71AV1 and its redox partner, POR (cytochrome P450 reductase) increased production by 3.6 fold, whereas combining four genes ADS, CYP71AV1, ALDH1, and POR from *A. annua* yielded a 3.4 fold increase in the artemisinin levels ([@B24]; [@B94]). Additionally, the production also increased by overexpression of ADS, CYP71AV1, and HMGR ([@B64]; [@B3]). The expression of several genes in the pathway clearly have an effect on the artemisinin level and do increase the amount of biomass obtained ([@B91]; [@B3]). Thus, utilizing genetic engineering to target the expression of both upstream and specific artemisinin genes should be pursued.

The overexpression of DBR2 clearly showed that this is a key enzyme that regulates the production of artemisinin by guiding the metabolic flow from artemisinic acid toward dihydroartemisinic acid. Without the activity of DBR2 the plants solely make artemisinic acid and thereby arteannuin B ([@B130]), thus showing that overexpression of this enzyme will enhance artemisinin production. Collectively, the overexpression studies have provided insights into the understanding of the pathway and how to upregulate it.

Another strategy in bioengineering is to block competing reactions such as the squalene synthase (SQS) and β-caryophyllene synthase, enzymes consuming FPP for sterol and β-caryophyllene biosynthesis. This has been proven to elevate artemisinin production by 3.14 and 5.49 fold, respectively ([@B128]; [@B22]). Since RED1 competes with ALDH1 in artemisinin biosynthesis of *A. annua*, removing RED1 could also lead to the increase of artemisinin production in *A. annua* ([@B89]).

FPS in general has a higher *k~cat~* value than sesquiterpene synthases and this is true for the FPS and ADS in *A. annua*. Thus, it has been investigated whether a fusion of the two enzymes would increase the turnover of FPP to amorphadiene ([@B43]). The findings that such fusion can facilitate metabolite channeling through a biosynthesis pathway has recently been shown for other metabolites ([@B55]). The metabolite channeling from FPS to ADS is supported by a 2--3 fold increase of amorphadiene in plants where these two genes are fused ([@B43]). The dynamic artemisinin content in the transgenic and wild type plants is associated with the expression of these genes involved in the artemisinin pathway. **Table [1](#T1){ref-type="table"}** summarizes the work on genetic manipulation in *A. annua* to improve the production of artemisinin.

###### 

Genetic engineering to improve the production of artemisinin in *Artemisia Annua.*

  Type                               Overexpressed enzymes           Artemisinin yield       Reference
  ---------------------------------- ------------------------------- ----------------------- ---------------------
  Upstream key enzymes               FPS                             13.0 mg/g (DW)          [@B44] [@B9] [@B21]
                                     HMGR                            1.7 mg/g (DW)           [@B6]
                                                                     0.6 mg/g (DW)           [@B71]
                                     AaIPP1                          2.5 mg/g (DW)           [@B65]
                                     AaHDR1                          0.09 mg/g (FW)          [@B66]
  Artemisinin biosynthesis enzymes   DXR                             1.21 mg/g (DW)          [@B121]
  with related key enzymes           CYP71AV1 and POR                0.98 mg/g (FW)          [@B91]
                                     HMGR and ADS                    1.73 mg/g (DW)          [@B2]
                                     FPS and ADS                     26 mg/g (DW)            [@B43]
                                     FPS, CYP71AV1, POR              2.90 mg/g (FW)          [@B24]
                                     ADS, CYP71AV1, ALDH1, and POR                           [@B94]
                                     ADS, CYP71AV1, POR              15.1 mg/g (DW)          [@B60]
                                     DBR2                            22.35 mg/g (DW)         [@B102]
                                     ALDH1                           25.34 mg/g (DW)         [@B101]
  Competitive pathway enzymes        SQS                             31.0 mg/g (DW)          [@B128]
                                     CPS                             3.56 mg/g (DW)          [@B22]
  Transcription factors              AaWRKY                          14.2 mg/g (DW)          [@B49]
                                     AaERF1 and AaERF2               9.1 and 8.1 mg/g (DW)   [@B125]
                                     AaORA                           11.9 mg/g (DW)          [@B61]
                                     AaMYC2                          15.3 mg/g (DW)          [@B92]
                                     AaNAC1                          23.5 mg/g (DW)          [@B63]
  Others                             Rol B                           7.30 ug/g (DW)          
                                     Rol C                           3.33 ug/g (DW)          [@B32]
                                     AaPYL9                          1.80 mg/g (FW)          [@B127]
                                     AtCRY1                          1.65 mg/g (DW)          [@B46]

Bioengineering the Regulation of Artemisinin Biosynthesis
---------------------------------------------------------

Over the last 20 years *Agrobacterium rol* A, B, and C genes have been shown to increase the biosynthesis of stress response metabolites in different plant families ([@B18]). *Rol* genes are a potential activator of secondary metabolites which directly upregulate artemisinin production by induction of the gene expression, leading to higher amounts of enzymes and thus more products. Transformation of *rol* genes in other *Artemisia* sp. resulted not only in the overexpression of artemisinin pathway genes, but also artemisinin content in the plant ([@B31],[@B32]; [@B4]). Integration of individual and combined *rol* B and C genes in *A. annua* increases the production of artemisinin by up to ninefold ([@B40]; [@B31],[@B32]).

Identifying transcription factors involved in regulating artemisinin production has also contributed to a higher production of artemisinin and was recently reviewed ([@B93]). Overexpression of the transcription factor AaWRKY1 shows a 4.4 fold increase of artemisinin compared to the control plant. Overexpression of another transcription factor jasmonate-responsive AP2/ERF-type; AaERF1 and AaERF2 increases the gene expression levels of ADS, CYP71AV1, and DBR2 resulting in a higher accumulation of artemisinin and artemisinic acid in *A. annua* ([@B93]). What is clear from recent work is that there are parts of the artemisinin pathway, which have promoters that are specific for trichomes ([@B23]). Therefore changing these to a strong constitutive promoter might be a novel engineering target with CRISPR/Cas9 technology.

Metabolic Engineering in *Nicotiana* spp.
-----------------------------------------

Introducing artemisinin pathway genes in heterologous plants has been successful in both stable and transient expression but the artemisinin yield is relatively low ([@B35]; [@B129]; [@B106]). Currently, only *Nicotiana* spp. has been used as the plant alternative in the artemisinin research as it is cheap, well-established with rapid growth and high biomass. The expression of ADS in *Nicotiana tabacum* resulted in an increased production of the first product amorpha-4,11-diene ([@B111]). The addition of CYP71AV1, DBR2, and ALDH1 produced 4 mg/g fresh weight of amorph-4,11-adiene in leaves followed by 0.01 mg/g dry weight of artemisinic alcohol ([@B129]). Stable expression of five multiple genes from the MVA and artemisinin pathway constructed in a single vector into *N. tabacum* produces 0.48--6.8 μg/g dry weight of artemisinin ([@B35]). However, transient expression combining ADS, FPS, HMGR, and CYP71AV1 in *N. benthamiana* produced artemisinic acid that was further modified by endogenous glycosyl transferase into artemisinic acid-12-β-diglucoside ([@B110]). There is a high production of glycosylated artemisinin precursors with the expression of artemisinin genes in *N. benthamiana* ([@B106]).

Glycosylation is a problem in the *Nicotiana* spp. ([@B110]; [@B106]). To overcome this, attempts were made to target the biosynthesis into different cellular compartments such as the chloroplast. [@B39] introduced the artemisinin pathway into *N. tabacum* chloroplast via a stable plastid genome transformation followed by a combinatorial transformation resulting in a transformation of transplastomic recipient lines (COSTREL) that produces 120 μg/g artemisinic acid.

Another group aimed to engineer two mega-metabolic pathways separately into two different cellular compartments. They first elevated the IPP pools by introducing six genes from MVA pathway into *N. tabacum* chloroplast followed by the artemisinin pathway genes into the nuclear genome with subcellular targeting at DBR2, CPR, and CYP71AV1 via chloroplast transit peptide. The lines produced ∼0.8 mg/g dry weight of artemisinin ([@B68]). While various methods were explored in order to enhance artemisinin production in *Nicotiana*, the production levels remain minimal due to the complex nature of the gene expression and regulation in artemisinin biosynthesis pathway as well as the complex glycosylation response in *Nicotiana*.

Metabolic Engineering in *Physcomitrella* Patens
------------------------------------------------

A new production platform is being established in a non-vascular plant, the moss *P. patens* ([@B96]; [@B19]; [@B48]; [@B86]). Having unique molecular tools of highly efficient homologous recombination and a fully sequenced genome, *P. patens* is an attractive production system when compared to other plant production hosts ([@B90]; [@B85]; [@B38]). Additionally, a novel transformation technology involving *in vivo* assembly of multiple DNA fragments in *P. patens* has been established, further increasing its attractiveness as a promising photosynthetic chassis for synthetic biology ([@B50]). This is also supported by several works utilizing *P. patens* as a "green factory," for example, the expression of taxadiene synthase in *P. patens* produces taxadiene without any phenotypic change, making it a capable host for the production of paclitaxel ([@B5]). In addition, three important sesquiterpenoids in the fragrance industry, patchoulol, β-santalene, and sclareol was also successfully produced in *P. patens* with productivity up to 1.3, 0.039, and 2.84 mg/g dry weight respectively ([@B126]; [@B77]). We recently reported the successful production of artemisinin in *P. patens* ([@B47]). All five artemisinin pathway genes were introduced into *P. patens* via the *in vivo* assembly of multiple DNA fragments method and the transgenic *P. patens* lines produces 0.21 mg/g DW of artemisinin, a significant level at only 3 days of culturing. A considerable advantage of *P. patens* as an artemisinin production platform is the absence of pathway intermediates (glycosylation and glutathione conjugation). *P. patens* has less glycosyltransferases as compared to higher plants that may lead to the possibility of lower risk of endogenous modifications to xenobiotic metabolites. Further research in bioengineering of *P. patens* for a higher artemisinin production is ongoing and could potentially help stabilize the supply of artemisinin and aid in containing malaria. Bioengineering of artemisinin biosynthesis pathway in heterologous *in planta* host with successful production of artemisinic acid and artemisinin is summarized in **Table [2](#T2){ref-type="table"}**.

###### 

Compilation of bioengineering works in heterologous *in planta* host producing artemisinin and artemisinic acid.

  Construct                                                                                                                                                                Strain                    Artemisinin      Artemisinic acid   Reference
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------ ------------------------- ---------------- ------------------ -----------
  Mega vector consisting HMGR, CYP71AV1, CPR, DBR2, cytosolic-targeting ADS and mitochondria-targeting ADS                                                                 *Nicotiana tabacum*       0.0068 mg/g DW   --                 [@B35]
  Transient expression of ADS, CYP71AV1, DBR2, ALDH1 with co-expression of lipid transfer proteins from *A. annua*                                                         *Nicotiana benthamiana*   0.0030 μg/g DW   --                 [@B112]
  FPS, ADS, CYP71AV1, CPR targeted at the chloroplast followed by combinatorial supertransformation of CYPB5, ADH1, ALDH1, DBR2                                            *Nicotiana tabacum*       --               120 μg/g FW        [@B39]
  Six MVA pathway genes, AACT, HMGS, HMGR, MVK, PMK, PMD transformed into chloroplast and subcellular targeting DBR2, CYP71AV1 and CPR via chloroplast transient peptide   *Nicotiana tabacum*       0.8 mg/g DW      --                 [@B68]
  Five artemisinin pathway genes, ADS, CYP71AV1, ADH1, DBR2, ALDH1 stably transformed into *Physcomitrella patens* via a novel *in vivo* DNA assembly method               *Physcomitrella patens*   0.21 mg/g DW     --                 [@B47]

Perspectives
============

Current advances in genetic and metabolic engineering drive a more diverse research and development approach on improving *in planta* production of artemisinin. The successes achieved in heterologous plant hosts and engineering of *A. annua* remains are of great importance. Microbial engineering of artemisinic acid shows some potential, but the added costs for later chemical synthesis of artemisinin is a detracting factor for replacing *A. Annua* as the main artemisinin source. Progress in plant engineering and synthetic biology has significantly improved the awareness of using plant as production hosts leading to great efforts in the implementation and enhancement of artemisinin production in both *in vivo* and *in vitro* production. Furthermore, heterologous *in planta* production seems to be more cost effective and environmentally friendly than other current biotechnological platforms. Advances in multigene transformation, transcription factors along with targeting of cellular compartment techniques will enable elevation of production levels in future engineered plants bringing us closer to industrial scale plant factories for artemisinin production. Perhaps the continuous production of artemisinin and other valuable plant metabolites in suspended bioreactor cultures with *in situ* extraction to avoid cell toxicity is not too far in the future. This will avoid the regulatory restrictions on in field GMO plants, and allow for stable continues production of drugs.
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